Genix Pharmaceuticals Corp.

Recent News

  • Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada's First Generic Thyroid Medication

    Vancouver, British Columbia,--(Newsfile Corp. - April 1, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") is pleased to announce that it has entered into an exclusive Canadian licensing and supply agreement (the "Agreement") with Acme Generics LLP ("ACME") for the manufacture, sale, marketing and distribution of Canada's first available generic version of Synthroid® (Levothyroxine sodium), a widely prescribed treatment for hypothyroidism. Currently sold by Mylan Pharmaceuticals, Synthroid® is the largest volume prescription drug...

    2021-04-01 8:55 AM ET
  • Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions (ANDS) for Its First Ten Ophthalmic Drugs with Health Canada

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") GENIX is pleased to announce that it has entered into an agreement with a regulatory consulting company to prepare and file Abbreviated New Drug Submissions (ANDS) with Health Canada for the first 10 of its 30 generic ophthalmic drugs, acquired by the Company.An ANDS is an application to Health Canada to approve a prescription generic pharmaceutical for sale in Canada. Upon approval...

    2021-03-22 8:50 AM ET
  • Genix Pharmaceuticals Corporation Announces AGM Results and Welcomes New Director

    Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces the results of its annual general meeting of shareholders ("AGM") held in Vancouver, British Columbia on September 18, 2020.Shareholders approved all the nominees listed in the management information circular (the "Circular"), which was mailed to GENIX shareholders of record as of August 17, 2020. The following were elected to the board of directors of the Company to hold office until the...

    2020-09-22 9:00 AM ET
  • Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and Closing of Acquisition of Rights to Nutraceutical Products Sucanon(R) and Renochlor(R)

    Vancouver, British Columbia--(Newsfile Corp. - August 6, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" of the "Company") is pleased to announce that it has closed the final tranche of its non-brokered private placement financing announced in its news releases dated June 22 and June 30, 2020. Genix announced the closing for the first tranche in the amount of $640,984 by news release dated July 17th, 2020 news release. The Company has issued 2,572,667 units of the Company...

    2020-08-06 10:15 AM ET
  • Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - July 17, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce it has closed an initial tranche of $640,984 under the non-brokered private placement (the "Private Placement") announced by news release dated June 22, 2020. The Private Placement was originally announced for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. Due to strong demand, Genix filed a price reservation form to increase the size...

    2020-07-17 3:24 PM ET
  • Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor(R), Sucanon(R) and Flu-x(TM)

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company and Canagen Pharmaceuticals Inc. ("Canagen") have mutually agreed to extend the closing dates for the payment terms ("Payment Terms") for the sole and exclusive distribution, sales and marketing rights and interest, excluding intellectual property rights, to certain nutraceutical products marketed and distributed under the brand names Renochlor® and Sucanon® as outlined in our news release...

    2020-06-30 8:53 PM ET
  • Genix Pharmaceuticals Corporation Announces Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. The Private Placement will consist of up to 3,750,000 units (excluding any over-allotment) of the Company (each a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share of the Company (a "Share")...

    2020-06-22 12:10 PM ET
  • Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)

    Vancouver, British Columbia--(Newsfile Corp. - March 27, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX)("GENIX" or the "Company"), announces that it has entered into an agreement, dated for reference March 24, 2020 (the "Agreement"), with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSXV"), the Company has agreed to purchase the sole and exclusive global distribution, sales and marketing rights and interest (the "Global Rights") for Flu-X®, a novel and proprietary, anti-viral, anti-flu...

    2020-03-27 9:00 AM ET